Meet Marci, Invasive Lobular Breast Cancer Survivor and Signatera™ Patient
Read Article
Oncology
Resources related to tests that help detect circulating tumor DNA for molecular residual disease assessment.
-
-
Signatera Explainer
Watch Video
-
Partnering in Survivorship: The Oncology-OB/GYN connection in breast cancer surveillance
Watch Video
-
Signatera MRD Testing for NSCLC Patient Management
Watch Video
-
Personalized ctDNA testing in Urothelial Cancer
Watch Video
-
ASH 2025 Signatera Data Highlights
Read More
-
New data. Better insight. The future of precision breast cancer management
Watch Video
-
Pan-Lymphoma Analysis Brochure
Read More
-
Understanding Signatera™ for Testicular Cancer
Read Article
-
An MRD-guided approach to advancing treatment strategies in gynecologic cancer
Watch Video
-
Shaping the future of skin cancer: Tumor-informed ctDNA-guided interventions
Watch Video
-
Understanding the SINERGY Trial: A More Personalized Approach to Treating Head & Neck Cancer
Read Article
-
From Detection to Decision-Making: Utility of Signatera in Complex GI & Hepatobiliary Malignancies
Watch Video
-
Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in
Ma VT., Zhou AY., Forati A., et al. JCO PO 2026
Read More
-
Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma
Ansstas G., Khaddour K., Sudhaman S., et al. CCR. 2026
Read More
-
Sensitivity of Circulating Tumor DNA for Detection of Minimal Residual Disease Recurrence or Relapse in Patients With Melanoma
Steimle AK., Harris MS, Forati A, et al. JCO OA. 2026
Read More
-
Circulating Tumor DNA Predicts Response After Definitive Radiation Therapy for Merkel Cell Carcinoma
Murchison, K., Camargo, A., Margalit, D., et al. Adv. Radiat. Oncol. 2026
Read More
-
Genomic profiling guided therapy for synchronous SCC and CLL of the parotid gland: a rare case report
Dahiya, R., Weiss, N., Wilson, P., et al. J Surg Case Rep. 2025
Read More
-
Personalized Circulating tumor DNA assay to assess long-term clinical benefit in patients with advanced melanoma
Martinez-Villa C, Teixido C, Martin R, et al. Cancers 2025
Read More
-
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management
Akaike T, Thakuria M, Silk AW, et al. J Am Acad Dermatol. 2025
Read More
-
Loading More...
